This is a preview of subscription content, log in via an institution to check access.
Reference
Matter-Walstra K, et al. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting. British Journal of Dermatology : 2 Sep 2015
Rights and permissions
About this article
Cite this article
Trametinib + dabrafenib not cost effective in Switzerland. PharmacoEcon Outcomes News 737, 27 (2015). https://doi.org/10.1007/s40274-015-2473-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2473-3